We are live on ! Find out more
EGRX

Eagle Pharmaceuticals, Inc.
EGRX

Delisted

EGRX was delisted on the 2nd of October, 2024.

Back to rankings

152 hedge funds and large institutions have $328M invested in Eagle Pharmaceuticals, Inc. in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 48 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

11,773% more call options, than puts

Call options by funds: $1.78M | Put options by funds: $15K

23% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 48

5% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 19

1% less funds holding

Funds holding: 153 → 152 (-1)

3% less capital invested

Capital invested by funds: $337M → $328M (-$8.86M)

Holders
152
Holders Change
-1
Holders Change %
-0.65%
% of All Funds
2.44%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
59
Reduced
48
Closed
19
Calls
$1.78M
Puts
$15K
Net Calls
+$1.77M
Net Calls Change
-$1.83M

Top Buyers

Rank Fund Capital Flow
1
LSV Asset Management
LSV Asset Management
Illinois
+$4.81M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.77M
3
Bank of Nova Scotia
Bank of Nova Scotia
Ontario, Canada
+$2.71M
4
Allspring Global Investments
Allspring Global Investments
North Carolina
+$1.99M
5
HF
HRT Financial
New York
+$1.94M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$39.7M
2
JP Morgan Chase
JP Morgan Chase
New York
-$3.83M
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$2.53M
4
Millennium Management
Millennium Management
New York
-$2.39M
5
Citadel Advisors
Citadel Advisors
Florida
-$2.27M
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
26
JP Morgan Chase
New York
$3.26M -$3.83M -120,391 -52%
Millennium Management
27
Millennium Management
New York
$2.62M -$2.39M -75,140 -46%
Bank of Nova Scotia
28
Bank of Nova Scotia
Ontario, Canada
$2.49M +$2.71M +85,293 New
N
29
Nuveen
North Carolina
$2.28M +$414K +13,013 +20%
SEI Investments
30
SEI Investments
Pennsylvania
$2.14M -$44.2K -1,390 -2%
ETM
31
Euclidean Technologies Management
Washington
$2.11M +$318K +10,000 +16%
Invesco
32
Invesco
Georgia
$2.1M +$131K +4,113 +6%
Principal Financial Group
33
Principal Financial Group
Iowa
$2.07M -$12.2K -384 -0.5%
Federated Hermes
34
Federated Hermes
Pennsylvania
$2.05M -$1M -31,523 -31%
Prudential Financial
35
Prudential Financial
New Jersey
$1.98M +$76.6K +2,410 +4%
HF
36
HRT Financial
New York
$1.78M +$1.94M +61,059 New
Rafferty Asset Management
37
Rafferty Asset Management
New York
$1.71M +$40.4K +1,272 +2%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$1.61M +$32.5K +1,023 +2%
UBS Group
39
UBS Group
Switzerland
$1.34M +$1.14M +35,780 +361%
AllianceBernstein
40
AllianceBernstein
Tennessee
$1.27M +$126K +3,978 +10%
Los Angeles Capital Management
41
Los Angeles Capital Management
California
$1.24M +$1.34M +42,276 New
Bank of America
42
Bank of America
North Carolina
$1.2M +$173K +5,442 +15%
William Blair & Company
43
William Blair & Company
Illinois
$1.14M -$101K -3,185 -8%
RA
44
Royce & Associates
New York
$1.03M +$360K +11,320 +47%
Squarepoint
45
Squarepoint
New York
$1.02M +$347K +10,910 +46%
Barclays
46
Barclays
United Kingdom
$1.01M -$140K -4,418 -11%
Citigroup
47
Citigroup
New York
$987K -$783K -24,613 -42%
ETC
48
Exchange Traded Concepts
Oklahoma
$972K +$32.2K +1,012 +3%
Qube Research & Technologies (QRT)
49
Qube Research & Technologies (QRT)
United Kingdom
$948K -$188K -5,899 -15%
Tudor Investment Corp
50
Tudor Investment Corp
Connecticut
$947K +$156K +4,921 +18%
1
2
3 4 5

EGRX Hedge Fund Activity: Q4 2022 in Review

152 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q4 2022, worth a combined $328M — down 2.6% from $337M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new EGRX positions and 19 closed out — a net gain of 1 holder — while 59 added to existing stakes and 48 trimmed.

The largest buyer was LSV Asset Management, opening a new position worth an estimated $4.81M. The largest seller was Janus Henderson Group, cutting an estimated $39.7M.

  • 152 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q4 2022, down from 153 in Q3 2022.
  • Funds reported $328M of Eagle Pharmaceuticals, Inc. stock for Q4 2022, down 2.6% quarter-over-quarter.
  • 20 funds opened new Eagle Pharmaceuticals, Inc. positions in Q4 2022 and 19 closed out, a net change of +1 holder.
  • The largest Eagle Pharmaceuticals, Inc. buyer in Q4 2022 was LSV Asset Management, an estimated $4.81M added.
  • The largest Eagle Pharmaceuticals, Inc. seller in Q4 2022 was Janus Henderson Group, an estimated $39.7M sold.

Based on aggregated 13F filings for Q4 2022.